ロード中...
Switching from first or second generation EGFR-TKI to osimertinib in EGFR mutation-positive NSCLC
AIM: We evaluated the efficacy of a novel switch protocol for EGFR-TKIs for EGFR mutation-positive NSCLC. MATERIALS & METHODS: Clinical records were collected from the patients who had received one of two sequential combination strategies of EGFR-TKIs: Salvage use of osimertinib for T790M-mediat...
保存先:
| 出版年: | Lung Cancer Manag |
|---|---|
| 主要な著者: | , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Future Medicine Ltd
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7186852/ https://ncbi.nlm.nih.gov/pubmed/32346403 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/lmt-2020-0005 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|